Metabolic alterations are increasingly implicated in neurological
disorders, including Alzheimer’s disease (AD), highlighting the
relevance of the peripheral metabolome, shaped by genetic and
environmental exposures, for brain health. We examined the relation of
991 blood metabolites with cognition and magnetic resonance imaging
(MRI) measures cross-sectionally in 1,082 dementia-free middle-aged
participants of the population-based Rotterdam Study and quantified
contributions of genetic variation, lifestyle, comorbidities, medication
and gut microbiota to metabolite variance. Cognition-associated
metabolites were replicated in two independent cohorts of older adults
and tested for associations with incident AD longitudinally in one
cohort. Twenty-two metabolites were associated with MRI measures.
Fourteen metabolites showed replicated associations with cognition, with
ergothioneine exhibiting the largest effect. The metabolite signature
of cognition mirrored that of incident AD. Lifestyle, clinical variables
and medication were the strongest determinants of cognition-associated
and MRI-associated metabolites, explaining up to 28.6% of their
variance. Antacid use was associated with worse cognition and lower
ergothioneine levels, which mediated 31.5% of the negative medication
effect, suggesting implications for AD prevention.
GrantsZonMw (Netherlands Organisation for Health Research and Development) Deutsche Forschungsgemeinschaft (German Research Foundation) U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging)